{'fraction_non_alphanumeric': 0.022328548644338118, 'fraction_numerical': 0.011164274322169059, 'mean_word_length': 5.680851063829787, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Mexiletine in the treatment of lidocaine-resistant ventricular tachycardia. Preliminary results].

Intravenous mexiletine (3 mg/Kg as bolus) was given to 7 patients with sustained ventricular tachycardia. Previous lidocaine administration in standard doses failed to suppress ventricular tachycardia. Mexiletine successfully suppressed the episodes of ventricular tachycardia in 6 of the 7 patients at a dose of 250 mg. Minimal non-cardiac toxicity occurred after mexiletine administration in the majority of patients. Mexiletine appears to be a promising alternative to lidocaine in the management of ventricular arrhythmias.